State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, PR China.
PLoS One. 2012;7(6):e40169. doi: 10.1371/journal.pone.0040169. Epub 2012 Jun 29.
Studies have been shown that miR-125a plays an important role in carcinogenesis, however, the role of miR-125a in hepatocellular carcinoma (HCC) remains elusive.
METHODOLOGY/PRINCIPAL: Real time-PCR (qRT-PCR) was performed to test the significance of miR-125a in HCC. Ectopic expression of miR-125a was used to test the influences of miR-125a on proliferation and metastasis of HCC cells in vitro and in vivo. Predicted target genes of miR-125a were determined by dual-luciferase reporting, qRT-PCR, and western blot (WB) analyses. Then immunohistochemical staining (IHC) was used to detect the expression of target genes, and the correlations and prognostic values of miR-125a and its target genes were also investigated.
CONCLUSIONS/SIGNIFICANCE: Decreased miR-125a was observed in both HCC tissues and cell lines, and associated with patients' aggressive pathologic features. Up-regulating miR-125a significantly inhibited the malignant phenotypes by repressing the expression of matrix metalloproteinase 11 (MMP11) and vascular endothelial growth factor A (VEGF-A) both in vitro and in vivo. Furthermore, miR-125a expression was inversely correlated with both MMP11 and VEGF-A expression in HCC tissues. Inhibiting miR-125a could increase both MMP11 and VEGF-A expression, and RNA interference targeting MMP11 or VEGF-A mRNA could rescue the loss of miR-125a functions. MiR-125a inhibits the proliferation and metastasis of HCC by targeting MMP11 and VEGF-A. Up-regulation of miR-125a might be a promising approach and a prognostic marker for HCC.
已有研究表明 miR-125a 在致癌作用中发挥重要作用,但 miR-125a 在肝细胞癌(HCC)中的作用仍不清楚。
方法/原理:采用实时 PCR(qRT-PCR)检测 miR-125a 在 HCC 中的意义。过表达 miR-125a 用于检测 miR-125a 对 HCC 细胞体外和体内增殖和转移的影响。通过双荧光素酶报告、qRT-PCR 和 Western blot(WB)分析确定 miR-125a 的预测靶基因。然后用免疫组织化学染色(IHC)检测靶基因的表达,并研究 miR-125a 及其靶基因的相关性和预后价值。
结论/意义:在 HCC 组织和细胞系中均观察到 miR-125a 表达降低,与患者侵袭性病理特征相关。上调 miR-125a 通过抑制基质金属蛋白酶 11(MMP11)和血管内皮生长因子 A(VEGF-A)的表达,显著抑制 HCC 细胞的恶性表型,无论是在体外还是体内。此外,miR-125a 在 HCC 组织中的表达与 MMP11 和 VEGF-A 的表达呈负相关。抑制 miR-125a 可增加 MMP11 和 VEGF-A 的表达,而针对 MMP11 或 VEGF-A mRNA 的 RNA 干扰可挽救 miR-125a 功能的丧失。miR-125a 通过靶向 MMP11 和 VEGF-A 抑制 HCC 的增殖和转移。上调 miR-125a 可能是 HCC 有前途的治疗方法和预后标志物。